Bristol Myers Squibb Company (NYSE:BMY – Free Report) – Erste Group Bank reduced their FY2026 earnings per share (EPS) estimates for Bristol Myers Squibb in a note issued to investors on Wednesday, October 21st. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will post earnings of $6.34 per share for the year, down from their prior forecast of $6.96. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.51 per share.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same quarter last year, the company earned $1.46 earnings per share. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.
BMY has been the topic of a number of other research reports. Morgan Stanley reaffirmed an “underweight” rating and issued a $41.00 price target (up from $40.00) on shares of Bristol Myers Squibb in a research report on Wednesday, October 7th. Daiwa Securities Group lifted their target price on Bristol Myers Squibb from $53.00 to $66.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. HSBC reissued a “hold” rating and issued a $65.00 target price (up from $60.00) on shares of Bristol Myers Squibb in a research report on Thursday, September 10th. Roth Capital initiated coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “buy” rating and a $75.00 price target on the stock. Finally, Zacks Research lowered Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $65.50.
Check Out Our Latest Stock Report on Bristol Myers Squibb
Bristol Myers Squibb Stock Up 0.0%
Shares of NYSE BMY opened at $61.63 on Monday. The stock has a fifty day simple moving average of $63.09 and a 200-day simple moving average of $59.85. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $68.64.
Institutional Investors Weigh In On Bristol Myers Squibb
Several hedge funds have recently modified their holdings of BMY. Davis Asset Management L.P. acquired a new position in Bristol Myers Squibb in the 2nd quarter valued at $27,000. Addison Advisors LLC acquired a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth $32,000. William Mack & Associates Inc. acquired a new stake in shares of Bristol Myers Squibb in the 3rd quarter worth $35,000. Groupe la Francaise boosted its holdings in shares of Bristol Myers Squibb by 562.9% in the second quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 501 shares in the last quarter. Finally, Kilter Group LLC purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at about $35,000. 76.41% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.05% of the company’s stock.
Bristol Myers Squibb Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.1%.
Trending Headlines about Bristol Myers Squibb
Here are the key news stories impacting Bristol Myers Squibb this week:
- Positive Sentiment: Encouraging cancer-drug data strengthens the growth pipeline. Izalontamab brengitecan (Iza-Bren) reportedly doubled median progression-free survival versus chemotherapy in previously treated EGFR-mutated non-small-cell lung cancer. Separate Phase 3 data indicated the drug reduced breast-cancer progression risk by as much as 38%. The results could support a future growth driver as Bristol Myers Squibb manages declines from older products. Iza-Bren lung cancer trial results
- Positive Sentiment: Valuation remains supportive. One analysis argues that BMY still trades below fair value based on expected future cash generation, despite its strong 12-month advance. Analysts also point to growth medicines and higher Eliquis guidance as potential offsets to legacy-portfolio weakness. BMY valuation analysis
- Neutral Sentiment: Third-quarter earnings are the next major catalyst. Preview coverage is focused on revenue trends, Eliquis performance, newer growth products and the pace of decline in older drugs. The market is waiting to see whether operating results support the company’s full-year EPS guidance of $6.75–$7.00. Q3 earnings preview
- Neutral Sentiment: Analyst sentiment is cautious but not bearish. Piper Sandler lowered its price target from $82 to $78 while retaining an Overweight rating, implying further upside. Zacks Research maintains a Hold rating and trimmed its Q3 2027, FY2027 and FY2028 EPS estimates only slightly, to $1.55, $6.23 and $5.21, respectively. Piper Sandler BMY target
- Negative Sentiment: Patent expirations remain the principal risk. Declining sales from key legacy medicines could pressure earnings, and estimates already imply lower profitability in later years. Investors must weigh the pipeline’s commercialization potential against this erosion. BMY bargain or value trap analysis
Bristol Myers Squibb Company Profile
Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.
The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.
Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.
Read More
- Five stocks we like better than Bristol Myers Squibb
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
